Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
January 2026: Amgen completed Phase 3 enrollment for MariTide (AMG 133) in the MARITIME-Obesity trial, with interim efficacy data expected in Q3 2026 that will position the monthly injection GLP-1/GIP antagonist as a once-monthly obesity treatment alternative
Goldenrod contributes diuretic, anti-inflammatory, and antimicrobial properties that support healthy urine flow and reduce urinary tract irritation
The second explanation, supported by morphological and behavioral evidence, is that the venom functions primarily as a deterrent against predators, not a predatory tool
Type 2 diabetes, in particular, has seen a continuous increase in prevalence, driven by lifestyle shifts and population aging, especially in Westernized societies, where these factors contribute to rising obesity rates
However, despite these encouraging preliminary findings, the current body of evidence is constrained by small sample sizes, heterogeneous study designs, and a lack of standardised imaging protocols, which collectively limit reproducibility and generalisability
They sit in a slowed stomach for hours
US$ 29.10
US$ 20.67
US$ 24.71
US$ 20.06
US$ 22.20
US$ 25.64
US$ 22.40
